24/7 Market News Snapshot 11 September, 2025 – GRI Bio, Inc. Common Stock (NASDAQ:GRI)

September 11, 2025

DENVER, Colo., 11 September, 2025 (www.247marketnews.com) – (NASDAQ:GRI) are discussed in this article.
GRI Bio, Inc. (GRI) is experiencing a notable surge in investor interest, with its stock price soaring to $2.347 during pre-market trading, reflecting a remarkable 50.45% increase from the prior close of $1.560. A trading volume of 2.11 million shares underscores the growing market enthusiasm surrounding the company. This significant momentum is indicative of strong investor sentiment and points to a potential upward trajectory for GRI, making its performance a prominent focus in the biotechnology sector.

In addition to the stock’s soaring valuation, GRI Bio is advancing its clinical research prominently through its Phase 2a clinical trial for GRI-0621, a new therapeutic candidate aimed at treating Idiopathic Pulmonary Fibrosis (IPF). Interim results from this trial reveal that patients receiving GRI-0621 have shown no decline in lung function, as measured by forced vital capacity (FVC), at the six-week mark. With 24 participants involved, this positive outcome builds on prior biomarker data suggesting an anti-fibrotic effect, characterized by significant alterations in serum biomarkers linked to reduced fibrosis formation and enhanced resolution.

Dr. Toby Maher, an authority in pulmonary medicine, highlighted the implications of these findings, asserting that GRI-0621 has not only demonstrated safety but also points to novel therapeutic pathways in treating fibrotic diseases. Marc Hertz, CEO of GRI Bio, shared optimism about upcoming topline data expected later this quarter, asserting that these findings could enhance treatment options for those affected by IPF, particularly in light of the limitations associated with existing therapies.

With the Phase 2a study fully enrolled at approximately 35 subjects, GRI Bio is setting the stage for significant advancements in the treatment landscape for fibrotic conditions. As the company continues to innovate, stakeholders eagerly anticipate further developments that may lead to meaningful improvements in patient care.

Related news for (GRI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.